• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Baker G Leonard Jr

    6/12/25 8:08:03 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BAKER G LEONARD JR

    (Last) (First) (Middle)
    755 PAGE MILL ROAD, SUITE A-200

    (Street)
    PALO ALTO CA 94304-1005

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CORCEPT THERAPEUTICS INC [ CORT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right To Buy) $72.27 06/10/2025 A 15,000 (1) 06/10/2035 Common Stock 15,000 $0.0000 15,000 D
    Explanation of Responses:
    1. Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly venting date.
    Remarks:
    The power of attorney under which this form was signed is on file with the Commission.
    /s/ Kanwalpreet S. Kalra, by power of attorney 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CORT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    11/18/2025Peer Perform
    Wolfe Research
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    7/27/2022$21.00 → $35.00Hold → Buy
    Jefferies
    6/27/2022$30.00 → $34.00Buy
    Canaccord Genuity
    More analyst ratings

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape

    10/28/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

    New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, meta

    10/19/25 5:15:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65, sold $1,601,526 worth of shares (20,000 units at $80.08), was granted 448 shares, gifted 787 shares and acquired 787 shares (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    12/3/25 9:19:27 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Maduck Sean sold $1,590,490 worth of shares (20,000 units at $79.52), was granted 410 shares, covered exercise/tax liability with 135 shares and exercised 20,000 shares at a strike of $8.27, increasing direct ownership by 3% to 8,179 units (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    12/3/25 8:53:43 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Lyon Joseph Douglas sold $397,632 worth of shares (5,000 units at $79.53), was granted 356 shares, covered exercise/tax liability with 110 shares and exercised 5,000 shares at a strike of $13.56, increasing direct ownership by 2% to 10,523 units (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    12/3/25 8:36:06 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Corcept Therapeutics

    Wolfe Research initiated coverage of Corcept Therapeutics with a rating of Peer Perform

    11/18/25 8:21:50 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics upgraded by Truist with a new price target

    Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously

    11/6/23 7:25:25 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Securities initiated coverage on Corcept Therapeutics with a new price target

    SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00

    4/11/23 7:25:02 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    SEC Filings

    View All

    SEC Form 10-Q filed by Corcept Therapeutics Incorporated

    10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    11/4/25 4:12:58 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    11/4/25 4:08:52 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    10/14/25 6:02:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Financials

    Live finance-specific insights

    View All

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape

    10/28/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

    7/31/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    Corcept Appoints Roberto Vieira as President, Oncology

    MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

    1/29/24 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Appoints Monica Tellado as President, Emerging Markets

    MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

    11/1/23 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Appointment of Three Senior Leaders

    MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

    4/7/22 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    3/27/24 2:32:52 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/14/24 4:23:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/13/24 5:02:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care